conditions

SMC Announces Marketing Agreement with Plato Technologies. Inc.

  BOCA RATON, FL / Plato / Amplifi / April 18,2024 / SMC Entertainment, Inc. ("SMC" or the "Company") (OTC PINK: SMCE) SMC / (PINK:SMCE) is pleased to announce a marketing agreement and collaboration with Plato Technologies Inc. Plato Technologies specializes in AI content disruption and AI management systems. The collaboration will enable the Company to market Plato's platform directly to web and content development teams. The companies have agreed on a revenue sharing agreement after deducting individual client acquisition costs. "This is just the beginning." stated Erik Blum CEO

Crypto.com’s Dubai Entity Receives Full Operational Approval

Crypto.com Exchange for Institutional Investors Launches as First Operational Milestone April 9, 2024, Dubai - Crypto.com, trusted by more than 80 million customers worldwide and the industry leader in regulatory compliance, security and privacy, announced today that its Dubai entity, CRO DAX Middle East FZE, has received full operational approval from Dubai’s Virtual Assets Regulatory Authority (VARA) and is launching the Crypto.com Exchange for institutional investors as its first operational milestone. This operational approval follows Crypto.com’s fulfillment of the pre-operational conditions stipulated in the Virtual Asset Service Provider Licence granted

StakingFarm Introduces a Strategic Blueprint for Crypto Staking Success Amid Market Volatility

  London, England – In an era defined by the digital revolution and the emergence of cryptocurrency as a formidable asset class, StakingFarm is proud to announce its advanced approach to crypto staking, designed to navigate the tumultuous waters of market volatility. This strategic blueprint is not merely a response to the fluctuations inherent in the crypto market; it is a comprehensive guide for investors seeking to maximize their earnings through staking crypto, transforming volatility from a challenge into an opportunity. "Volatility in the crypto market is not a barrier;

D8X Re-Engineers DeFi Derivatives With Launch on Polygon zkEVM

  Supported by Polygon Ventures, D8X targets institutional users with next-gen DEX engine, innovative features, novel white-label approach [Zug, Switzerland - Feb. 6, 2024] - D8X, an institutional-grade decentralized exchange (DEX) for derivatives, has launched on Polygon zkEVM, establishing a new benchmark for decentralized finance. With support from Polygon Ventures and other notable partners, D8X reconceives on-chain derivatives, starting from fundamental financial engineering and extending to its novel white-label business-to-business model–a first for Polygon zkEVM. Until now, users seeking the trading experience offered by D8X have had to resort to

Bracket Labs Announces $2 Million Pre-Seed Raise to Support the Launch of its ‘Passages’ Trading Platform

PANAMA CITY FLA – January 4, 2024 – Bracket Labs completed a $2 million pre-seed fundraise round to support the launch of "Passage," a volatility trading product available on the project’s BracketX trading platform. The debut of the range-bound product makes trading long and short volatility entirely on-chain easy for traders of all levels. In June 2023, Bracket Labs completed Binance Labs’ Season 5 Incubation Program and received investment from Binance Labs. In addition to completing the Incubation Program, Bracket Labs completed its pre-seed investment round from other notable crypto

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

  In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis

Zilliqa partners with GMEX ZERO13 to launch consumer-focused carbon offset platform

  LONDON, 27 September 2023 – Zilliqa, a leading layer-1 blockchain offering high-performance, high-security and low-fee solutions, today announces a partnership with GMEX Group and its initiative ZERO13, the digital climate fintech aggregation ecosystem, to launch the first-of-its-kind carbon offset platform that will transform the way that retail customers engage with corporate environmental initiatives. Together, Zilliqa Group and GMEX ZERO13 will deliver a cutting-edge platform that uses the blockchain-based currency, EVP, to represent carbon credit offsets. When they purchase goods or services, customers of brands partnered with Zilliqa will receive

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Livento Group, Inc. Announces Second Quarter Results with Revenue Growth of Over 90%, Including Significant Achievements and Updates

NEW YORK, NY / August 14, 2023 / NuGene International, Inc./Livento Group, Inc. (OTC Pink:NUGN), a dynamic leader specializing in the acquisition and development of companies with disruptive business models in film, content, and technology sectors, is pleased to announce revenue growth of 91.65% for the second quarter of 2023, compared to the same period in 2022. Financial Highlights: Revenue Growth:The second quarter ending June 30, 2023, saw revenues of $431,184, up from $224,986 in 2022. For the six-month period ending June 30, 2023, revenues grew from $680,202 to $922,651, a growth of

Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings

ORLANDO, FL / July 27, 2023 / Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of its consumer sports recovery tape brand, Active Intelligence AI Tape (“AI Tape”), with products now available for purchase on Amazon and Activeintell.com. AI Tape is designed to combine many of the traditional benefits of kinesiology tape with the addition of soothing and therapeutic ingredients held in suspension with a proprietary adhesive mix. “We are very excited for the launch of our AI Tape brand, our first products targeting the consumer